Clinical Trial

Phase I Study of FXS0683 in the Treatment of Blood Tumors

Study acronym: FXS0683-001
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, multicenter, open-label, single-arm Phase I study of FXS0683 in participants with relapsed or refractory hematologic malignancies to evaluate safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity, and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
Trial Details
NCT Number NCT07616089
Lead Sponsor Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
Enrollment 228 participants
Start Date 2026-06-01
Primary Completion 2028-08-07 (estimated)
Study Completion 2029-08-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-29